TIDES 2026

As advanced modalities move more rapidly into the clinic, CMC risk has become a critical determinant of development success. Peptides, oligonucleotides, mRNA‑based therapies, and sophisticated delivery systems demand greater rigor in formulation, stability, and analytics – particularly at the drug product level.

At TIDES USA 2026 in Boston, the global community comes together to explore how science‑driven CMC strategies can reduce late‑stage risk, strengthen comparability, and support faster, more confident decision‑making from early development through commercialization.

Coriolis Pharma at TIDES

Coriolis Pharma supports the development of peptide‑ and nucleic acid‑based therapeutics through specialized services in formulation development, stability studies, and advanced analytical characterization. Our experience spans:

• Peptides (linear and complex)
• Oligonucleotides (ASOs, siRNA, miRNA)
• Complex nucleic acid products, including mRNA LNPs and gene‑editing systems

As an independent, science‑driven partner, Coriolis helps teams understand critical quality attributes, identify formulation‑dependent risks, and avoid late‑stage surprises.

Let’s connect

If you’re attending TIDES USA 2026, we would be happy to connect and discuss how we can help you to de‑risk complex modalities from preclinical development to market.

Visit us at booth #829 or feel free to schedule a meeting with our team in advance to ensure dedicated time for discussion.

In addition, on the evening of May 12, 2026, we are hosting an exclusive offsite event—an opportunity to connect with peers, exchange insights on current development challenges, and engage in meaningful conversations beyond the conference agenda. Register here to join us.